TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Aug 27, 2020 17:05 JST
Source:
Sihuan Pharmaceutical Holdings Group Ltd.
Sihuan Pharmaceutical Launched an Equity Incentive Plan to Inject New Impetus for the Company's Growth
HONG KONG, Aug 27, 2020 - (ACN Newswire) - Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460 "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") announced that on 26 August 2020, the Company granted a total of 94,656,000 share options (the "Share Options") to the eligible participants of the Company (the "Grantees") to subscribe for a total of 94,656,000 ordinary shares of HK$0.01 each in the share capital of the Company (the "Shares") pursuant to the share option scheme of the Company adopted on 24 October 2017, subject to the acceptance by the Grantees.
Among the total of 94,656,000 Share Options granted, 19,000,000 Share Options were granted to five Directors, and the remaining 75,656,000 Share Options were granted to eligible participants who are employees of the Company. The exercise price of the share options granted HK$0.972 per share, closing price of the shares on the date of grant was HK$0.900 per share, average closing price of the shares for the five business days immediately preceding the date of grant was HK$0.972 per share. Validity period of the options start from 26 August 2020 to 25 August 2030 (both days inclusive).
About Sihuan Pharmaceutical Holdings Group Ltd.
Founded in 2001, Sihuan Pharmaceutical is a pharmaceutical group with 21 subsidiaries and integrated R&D, production and marketing and sales capabilities. Because of the continuing efforts over the past decade, Sihuan Pharmaceutical has formed a R&D platform with over 1,000 researchers conducting more than 110 pharmaceutical research projects currently. More than 300 patents on innovative drugs were granted in China and over 80 are PCT patents, covering pipeline projects including important areas of diabetes, oncology, anti-infectives and non-alcoholic steatohepatitis etc.
For more information about Sihuanpharm, please visit the company website
https://www.sihuanpharm.com/
.
Source: Sihuan Pharmaceutical Holdings Group Ltd.
Sectors: Daily Finance, Daily News
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Related Press Release
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical: The NDA of the New Drug, independently developed for the treatment of advanced breast cancer was accepted by NMPA
October 17 2023 16:01 JST
Sihuan Pharmaceutical Was Selected As One Of The First Echelon Of Enterprises In The list of China's Top 100 Pharmaceutical Innovative Enterprises in 2023
October 13 2023 18:07 JST
Sihuan Pharmaceutical (0460.HK) Announces 2023 Interim Results, Revenue amounted to RMB1,055.7 million
August 31 2023 13:50 JST
Sihuan Pharmaceutical (0460.HK): Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval For Clinical Trial
July 05 2023 09:49 JST
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA
June 27 2023 13:00 JST
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, progresses at full speed in innovative research and development, Presents major research results of birociclib, the start product, at the international stage in ASCO
June 08 2023 21:18 JST
Sihuan Pharmaceutical (0460.HK) Announces 2022 Annual Results
March 24 2023 19:16 JST
Sihuan Pharmaceutical (0460.HK): Huisheng Biopharmaceutical Successfully Completes A+ Round of Financing, Accelerating the Layout of Diabetes and Complications
January 04 2023 09:55 JST
Sihuan Pharmaceutical (0460.HK): Respond to the special directives to combat illegal medical aesthetics services, Advocate 'Positive Energy' in China's Medical Aesthetics Industry
August 11 2021 16:55 JST
Sihuan Pharmaceutical Announces 2020 Interim Results
August 25 2020 21:26 JST
More Press release >>
Latest Press Release
HKTDC 4Q25 Export Confidence Index: 2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion
Dec 12, 2025 23:15 JST
Anime Tokyo Station: A Series of Linked Events to Be Held in Conjunction with the Anniversary Joint Exhibition
Dec 12, 2025 11:00 JST
MHI and Worley to Deliver Full-Scale Carbon Capture Facility for Heidelberg Materials UK's Padeswood Cement Works
Dec 08, 2025 17:00 JST
Honda Technical Support for Red Bull Powertrains in F1 Racing Concludes
Dec 08, 2025 16:34 JST
MHIET U.S. Subsidiary's Franklin Plant Celebrates 10th Anniversary
Dec 08, 2025 16:03 JST
Lexus World Premieres Lexus LFA Concept BEV Sports Car
Dec 05, 2025 19:13 JST
TOYOTA GAZOO Racing World Premieres GR GT & GR GT3
Dec 05, 2025 18:58 JST
TOYOTA GAZOO Racing and Lexus Hold World Premiere of GR GT, GR GT3, and Lexus LFA Concept
Dec 05, 2025 18:24 JST
World's First General Design Approval (GDA) for Developed Steel and Post-Weld Heat Treatment (PWHT) Exemption based on ECA for Low-pressure Liquefied CO2 Tank made of KF460 steel
Dec 05, 2025 18:17 JST
Hitachi at CES 2026: Building a Harmonized Society Through Technology
Dec 04, 2025 19:40 JST
Fujitsu and Scaleway partner to accelerate European sustainable transformation and data sovereignty with FUJITSU-MONAKA CPU-based AI inference
Dec 04, 2025 19:08 JST
NEC Orchestrating Future Fund Invests in PopID, Inc. to Accelerate Global Expansion of Biometric Payment Solutions and Launch a Strategic Collaboration
Dec 04, 2025 18:52 JST
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
Dec 04, 2025 18:36 JST
The 26th Hong Kong Forum marks successful completion
Dec 03, 2025 22:44 JST
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
Dec 03, 2025 18:19 JST
Mitsubishi Motors Launches the All-New Destinator in Vietnam
Dec 03, 2025 18:00 JST
Anime Tokyo Station: Celebrating the 25th Anniversaries of Two Popular Anime with an Anniversary Joint Exhibition Starting November 15
Dec 03, 2025 11:30 JST
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Dec 03, 2025 00:01 JST
NEC Launches AI Agent Service in Japan to Automate Procurement Negotiations Using AI
Dec 02, 2025 23:43 JST
Fujitsu develops new technology to support human-robot collaboration
Dec 02, 2025 23:26 JST
More Latest Release >>